(Q35900446)

11 August 2017

In vitro activity of Bay Y3118 against anaerobic bacteria (English)

1 reference

11 August 2017

3

Finegold SM

1 reference

11 August 2017

Wexler HM

1

1 reference

11 August 2017

Molitoris E

series ordinal

2

1 reference

11 August 2017

language of work or name

English

0 references

publication date

1 November 1993

1 reference

Antimicrobial Agents and Chemotherapy

11 August 2017

1 reference

11 August 2017

37

1 reference

11 August 2017

11

1 reference

11 August 2017

2509-2513

1 reference

The in-vitro activity of Bay y 3118, a new chlorofluoroquinolone

11 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=192422

Susceptibilities of 428 gram-positive and -negative anaerobic bacteria to Bay y3118 compared with their susceptibilities to ciprofloxacin, clindamycin, metronidazole, piperacillin, piperacillin-tazobactam, and cefoxitin

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=192422

Comparative activity of the quinolones against anaerobic bacteria isolated at community hospitals

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=192422

Activity of pefloxacin and thirteen other antimicrobial agents in vitro against isolates from hospital and genitourinary infections.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=192422

Comparative activity of ciprofloxacin against anaerobic bacteria

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=192422

Is ciprofloxacin active against clinically important anaerobes?

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=192422

Comparative in vitro activities of a new quinolone, WIN 57273, and piperacillin plus tazobactam against anaerobic bacteria

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=192422

Susceptibility testing of anaerobic bacteria: myth, magic, or method?

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=192422

Comparative activity of ciprofloxacin, ofloxacin, sparfloxacin, temafloxacin, CI-960, CI-990, and WIN 57273 against anaerobic bacteria

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=192422

In vitro activities of three of the newer quinolones against anaerobic bacteria

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=192422

The comparative in-vitro activity of eight newer quinolones and nalidixic acid.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=192422

Comparative in vitro activity of lomefloxacin, a new difluoroquinolone.

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=192422

In-vitro and in-vivo potency of five new fluoroquinolones against anaerobic bacteria

24 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/8285647

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1128/AAC.37.11.2509

1 reference

release_wrplty54hjemvepvuxqtyfoeoi

11 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/wrplty54hjemvepvuxqtyfoeoi

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

11 August 2017

PubMed publication ID

8285647

1 reference